drugset / Trial / NCT00788112
Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast
Phase 1
Completed
17 enrolled
University of California, San Francisco
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelOther
Summary
RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This clinical trial is studying how well vorinostat works in treating women with ductal carcinoma in situ of the breast.
Timeline
- Start
- 2009-07
- Primary completion
- 2011-11-03
- Completion
- 2015-08-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vorinostat | Small molecule | — | Oral |